{
  "nctrialId": "HC-1684",
  "title": "A Randomized Double-Blind, Placebo-Controlled  Study of ARH-921 (JAK inhibitor) in Patients With Type 2 Diabetes",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled  Study of ARH-921 (JAK inhibitor) in Patients With Type 2 Diabetes",
  "sponsor": "McGill University Health Center",
  "indication": "Type 2 Diabetes",
  "phase": "Phase 1/Phase 2",
  "fileName": "HC-1684.json",
  "fileSize": 212983,
  "date": "2024-12-18",
  "completionDate": "2028-07-09",
  "drugName": "ARH-921 (JAK inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Not yet recruiting",
  "description": "This is a randomized double-blind, placebo-controlled  study designed to evaluate the efficacy and safety of ARH-921 (JAK inhibitor) in patients with Type 2 Diabetes. The study will enroll approximately 333 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 18-60 years\n- Confirmed diagnosis of Type 2 Diabetes\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n- HbA1c between 7.0% and 10.0%\n- Body mass index (BMI) between 25 and 40 kg/m²\n- On stable antidiabetic medication for ≥3 months\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment\n- History of severe hypoglycemia within past 6 months\n- Estimated GFR <45 mL/min/1.73m²\n- History of diabetic ketoacidosis"
}